As a child of Haitian immigrants in Queens, Rachelle Monteau watched her uncle struggle with leukemia.
Keytruda (pembrolizumab) has received an expanded label use from FDA as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
The United Kingdom plans to join two international initiatives that will allow pharmaceutical companies to submit medicines to be reviewed by several countries at the same time, pooling resources and allowing patients to benefit from earlier access.
MD Anderson Cancer Center and Allogene Therapeutics Inc. have entered into a five-year collaboration agreement for the preclinical and clinical investigation of AlloCAR T candidates across Allogene's portfolio of hematologic and solid tumors.
Data from the NCI-MATCH precision medicine trial established a new benchmark for next-generation sequencing in clinical trials.
Miami Cancer Institute researchers found that the overall median survival for patients with brain metastases has improved over time.
Napo Pharmaceuticals Inc., a wholly owned subsidiary of Jaguar Health Inc., has initiated its pivotal phase III clinical trial of crofelemer (Mytesi) for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy.
The phase II clinical study EV-201 evaluating the antibody-drug conjugate Padcev (enfortumab vedotinejfv) for treatment of urothelial cancer demonstrated a 52% overall response rate in the second cohort.
Researchers at the UCLA Jonsson Comprehensive Cancer Center have found that a virus-mimicking drug, BO-112, may also make certain stealthy melanoma tumors visible to the immune system, allowing them to be better targeted by immunotherapy.
